Heart failure results in high adult hospitalization and mortality rates worldwide. In developed countries, the prevalence of heart failure is reported in up to 2% of the total adult population and 10% in those older than 70 years.[@B1] Furthermore, the mortality of heart failure is very high after initial diagnosis, around 30% at 1 year and 50% at 5 years.[@B2] In the acute heart failure state, in-hospital mortality is reported at 28%, while that of cardiogenic shock is 40% to 80%.[@B3]

Cardiac resynchronization therapy (CRT) has been established as an effective treatment for symptomatic advanced heart failure patients with wide QRS duration despite having exhausted all other optimal medical therapy.[@B4] CRT can improve hospitalization and mortality rates by correcting unfavorable left ventricular hemodynamics or dyssynchrony.[@B5][@B6] However, since nearly one-third of patients have not experienced any benefit from CRT implantation at a significant financial cost, identifying CRT responders remains a challenging task in clinical practice.[@B7][@B8] Improvements of left ventricular systolic function and synchrony were commonly evaluated in previous studies. The right ventricle (RV) is also a crucial contributor to prognosis of advanced heart failure.[@B9][@B10] Therefore, the prognostic value of RV function for CRT referral patients is as yet to be identified and needs further evaluation through clinical study.

In this issue of *Journal of Cardiovascular Imaging*, Bragança et al.[@B11] investigated the clinical correlations and prognostic values of right ventriculo-arterial coupling (RV-PA) in heart failure patients undergoing CRT. They demonstrated that RV-PA coupling estimated by tricuspid annular plane systolic excursion and pulmonary artery systolic pressure ratio (TAPSE/PASP) showed excellent discriminative power for predicting response to CRT, and that PASP was independently associated with overall mortality in this group of heart failure patients. In addition, they suggested a novel cut-off value of baseline TAPSE/PASP ratio as 0.44 mm/mmHg for detection of a CRT non-responder, with good accuracy (area under the curve 0.76). Also, among CRT responders, improvements of RV-PA coupling were noted during follow-up in those showing elevated TAPSE and TAPSE/PASP ratio. However, this study has limitations of a small sample size and performed at a single center with a retrospective design in which selection bias was inevitable. Moreover, the echocardiographic-based TAPSE/PASP was not compared with the gold-standard method of right heart catheterization or cardiac magnetic resonance. Nonetheless, these findings provide a basis for consideration of right heart and pulmonary circulation in CRT referred patients using the easily performed echocardiographic-based TAPSE/PASP ratio method. This approach deserves further exploration.

In conclusion, Bragança et al.[@B11] found that RV-PA coupling as estimated by TAPSE/PASP ratio can be used as a significant prognostic marker in heart failure patients undergoing CRT. Further studies are warranted in numbers large enough to be statistically significant when using a prospective design.
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